ICAP Grand Rounds Webinar- Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls
Two recent landmark HIV Prevention Trials Network (HPTN) studies demonstrated the efficacy of long-acting, injectable cabotegravir (CAB) as PrEP against HIV. These studies showed that CAB for PrEP injected once every eight weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for PrEP among cisgender men and transgender women who have sex with men (HPTN 083) and cisgender women (HPTN 084). Both studies demonstrated that CAB for PrEP was well-tolerated, offering a new and important PrEP option for individuals at risk for HIV infection.
As regulatory approvals for CAB for PrEP move forward, Raphael J. Landovitz, MD, MSc, the HPTN 03 Protocol chair, will discuss findings from the randomized controlled trial and ongoing open-label extension phases of the studies, including some thoughts on opportunities and challenges of clinical implementation in this grand rounds.
This webinar is being presented by ICAP. Based at Columbia University with operations in more than 30 countries, ICAP is a leader in global public health, internationally known for tackling the world’s toughest health challenges—from HIV to tuberculosis, from malaria to maternal and child health, and the growing problem of non-communicable diseases, and most recently, the COVID-19 pandemic. Through innovative research, collaborative technical assistance, and a focus on strengthening health systems, ICAP helps to create better, more accessible, health services to reduce the burden of illness on people and communities.
What can modelling tell us about the scale-up of CAB for PrEP?
This factsheet summarises the results of mathematical modelling exercises of Cabotegravir (CAB) for PrEP rollout undertaken by researchers affiliated with the HIV Modelling Consortium. These results can help implementers and policymakers understand what to expect and guide early policy decisions to ensure CAB for PrEP is able to have maximum impact on reducing the HIV…
Daily Oral PrEP, Event-Driven PrEP, PrEP Ring, and CAB PrEP Template Guidelines (English)
The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based daily and event-driven oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and…
Quality Improvement Brief
The Quality Improvement Collaborative (QIC) is a component of the CATALYST study that refines and makes context-specific improvements to the enhanced service delivery package to make it scalable for delivering PrEP choice. The QIC’s multi-country design enables rich learning and problem-solving by providing QI faculty, advisors, coaches, and teams from all CATALYST countries opportunities to…
Insights Report: Communicating the PrEP Category to AGYW
PrEP Category Positioning Market Research Validation Insights from Kenya, South Africa, and Zimbabwe This report is a comprehensive look at what was learned through validating the positioning direction. It explains the methodology, outlines country-specific reactions to the positioning direction, and distills key findings that were leveraged to adjust and refine the positioning to honor the…
Communicating the PrEP Category to Adolescent Girls and Young Women
This strategy brief is intended for use by implementers working to generate demand for PrEP among AGYW. Drawing on all learnings throughout the positioning process, the brief provides a narrative explanation of how to communicate the PrEP category to AGYW and includes actionable guidance on how best to develop communication that will get the attention…
Efficacy and Safety of Long-Acting Cabotegravir Compared with Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine to Prevent HIV Infection in Cisgender Men and Transgender Women who Have Sex with Men 1 Year after Study Unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
This article from The Lancet HIV describes findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study, which compared safety and efficacy of cabotegravir and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as HIV prevention for transgender women and men who have sex with men in Argentina, Brazil, Peru, South Africa, Thailand, the…
Advocates’ Primer on Injectable Cabotegravir for PrEP
This document, designed for advocates, focuses on injectable cabotegravir for PrEP, outlining what’s known and what’s next for this emerging biomedical HIV prevention strategy. A summary slide deck with additional details can be found here.
CAB PrEP Value Chain Situation Analysis – Uganda – 2022
This analysis was developed in the fall of 2022 by members of the MOSAIC consortium. This analysis is based on several inputs, including a desk review, secondary research, and interviews with key stakeholders in Uganda.
Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis in Transgender Women: A secondary analysis of the HPTN 083 trial
This article from the Lancet HIV discusses the results of a secondary analysis of data from the HPTN 083 trial of cabotegravir for PrEP, looking specifically at the cohort of transgender women included in the study.
Normative Guidance/Policies, Service Delivery, Vertical Transmission
Elimination of vertical transmission of HIV will require expanded access to HIV prevention strategies, such as PrEP, for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of HIV pre-exposure prophylaxis (PrEP) to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that…